Aclarion shares surge 14.41% after hours after announcing cash runway into 2028 and CLARITY trial readouts.

Aclarion (ACON) surged 14.41% in after-hours trading following the release of its 2026 shareholder letter, which outlined a strengthened financial position and strategic focus on clinical milestones. The company emphasized a cash runway into 2028, eliminating dilution risks by terminating its at-the-market (ATM) equity program in early 2025 and allowing its equity line of credit (ELOC) to expire by year-end 2025. Management highlighted full funding for the CLARITY trial’s initial internal readout in Q3 2026 and public interim results in Q4, reinforcing confidence in its cloud-based, software-native MedTech model with scalable gross margins. The letter underscored a commitment to shareholder alignment by avoiding new capital raises until post-trial data disclosure, addressing investor concerns over dilution. These developments, coupled with a clear path to key clinical catalysts, drove the significant post-market rally.